Relmada Therapeutics (RLMD) Non-Current Debt (2017 - 2018)
Relmada Therapeutics (RLMD) reported Non-Current Debt of $3.2 million for Q3 2018, up 370.33% year-over-year from $678875.0 in Q3 2017, and up 20.2% quarter-over-quarter from $2.7 million in Q2 2018.
Relmada Therapeutics (RLMD) Non-Current Debt (2017 - 2018) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of Non-Current Debt data on file, last reported at $3.2 million in Q3 2018.
- Non-Current Debt for Q3 2018 came in at $3.2 million, up 370.33% year-over-year; the trailing twelve-month figure through Sep 2018 was $3.2 million (up 370.33% YoY), and the FY2018 annual result was $2.7 million, changed N/A from the prior year.
- Non-Current Debt grew to $3.2 million in Q3 2018 per RLMD's latest filing, from $2.7 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $3.2 million in Q3 2018 and troughed at $678875.0 in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 3.19 Mn |
| Sep 30, 2018 | 3.19 Mn |
| Jun 30, 2018 | 2.66 Mn |
| Jun 30, 2018 | 2.66 Mn |
| Mar 31, 2018 | 1.58 Mn |
| Mar 31, 2018 | 1.58 Mn |
| Dec 31, 2017 | 1.28 Mn |
| Dec 31, 2017 | 1.28 Mn |
| Sep 30, 2017 | 678,875.00 |
| Sep 30, 2017 | 678,875.00 |